COMMUNICATION Selective inhibition of Ab42 production by NSAID R-enantiomers

Non-steroidal anti-inflammatory drugs (NSAIDs) have been associated with reduced risk for Alzheimer’s disease (AD) and selected NSAIDs racemates suppress b-amyloid (Ab) accumulation in vivo and Ab42 production in vitro. Clinical use of NSAIDs for preventing or treating AD has been hampered by dose-limiting toxicity believed to be due to cyclooxygenase (COX)-inhibition that is reportedly not essential for selective Ab42 reduction. Profens have racemates and R-enantiomers were supposed to be inactive forms. Here we demonstrate that R-ibuprofen and R-flurbiprofen, with poor COX-inhibiting activity, reduce Ab42 production by human cells. Although these R-enantiomers inhibit nuclear factorjB (NF-jB) activation and NF-jB can selectively regulate Ab42, Ab42 reduction is not mediated by inhibition of NF-jB activation. Because of its efficacy at lowering Ab42 production and low toxicity profile, R-flurbiprofen is a strong candidate for clinical

[1]  D. Coppola,et al.  Microglial Activation and β-Amyloid Deposit Reduction Caused by a Nitric Oxide-Releasing Nonsteroidal Anti-Inflammatory Drug in Amyloid Precursor Protein Plus Presenilin-1 Transgenic Mice , 2002, The Journal of Neuroscience.

[2]  Rong Wang,et al.  A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity , 2001, Nature.

[3]  J. Overmier,et al.  Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice , 2001, Neurobiology of Aging.

[4]  M. Murakami,et al.  Coupling between Cyclooxygenase, Terminal Prostanoid Synthase, and Phospholipase A2 * , 2001, The Journal of Biological Chemistry.

[5]  P. Keegan,et al.  Early clinical trials of chemopreventive and biologic agents: Designs, populations, and endpoints. , 2001, Urology.

[6]  S. Grösch,et al.  Inhibition of NF‐ κ B and AP‐1 activation by R‐ and S‐flurbiprofen 1 2 , 2001 .

[7]  K. Ashe,et al.  Ibuprofen Suppresses Plaque Pathology and Inflammation in a Mouse Model for Alzheimer's Disease , 2000, The Journal of Neuroscience.

[8]  C. Plata-salamán,et al.  Inflammation and Alzheimer’s disease , 2000, Neurobiology of Aging.

[9]  H. Schaible,et al.  Inhibition of Noxious Stimulus‐Induced Spinal Prostaglandin E2 Release by Flurbiprofen Enantiomers , 2000, Journal of neurochemistry.

[10]  S. Tomita,et al.  PDZ Domain-dependent Suppression of NF-κB/p65-induced Aβ42 Production by a Neuron-specific X11-like Protein* , 2000, The Journal of Biological Chemistry.

[11]  William J. Ray,et al.  A presenilin-1-dependent γ-secretase-like protease mediates release of Notch intracellular domain , 1999, Nature.

[12]  J. McCray,et al.  Clinical Endoscopic Evaluation of the Gastroduodenal Tolerance to (R)‐ Ketoprofen, (R)‐ Flurbiprofen, Racemic Ketoprofen, and Paracetamol: A Randomized, Single‐Blind, Placebo‐Controlled Trial , 1998, Journal of clinical pharmacology.

[13]  A. Pahl,et al.  Modulation of transcription factor NF‐κB by enantiomers of the nonsteroidal drug ibuprofen , 1998, British journal of pharmacology.

[14]  R. Brugger,et al.  Effects of ibuprofen enantiomers and its coenzyme A thioesters on human prostaglandin endoperoxide synthases , 1997, British journal of pharmacology.

[15]  D. Selkoe,et al.  Alzheimer's Disease--Genotypes, Phenotype, and Treatments , 1997, Science.

[16]  Douglas Walker,et al.  Inflammation and Alzheimer's disease pathogenesis , 1996, Neurobiology of Aging.

[17]  H. Schaible,et al.  New Insights into the Site and Mode of Antinociceptive Action of Flurbiprofen Enantiomers , 1996, Journal of clinical pharmacology.

[18]  T. Torgerson,et al.  Inhibition of Nuclear Translocation of Transcription Factor NF-κB by a Synthetic Peptide Containing a Cell Membrane-permeable Motif and Nuclear Localization Sequence (*) , 1995, The Journal of Biological Chemistry.

[19]  S. Younkin.  Evidence that Aβ42 is the real culprit in alzheimer's disease , 1995 .